Interview with Aethlon Medical, Inc. President and Chief Executive Officer, James Joyce

Technology that Reduces the Presence of Infectious Disease and Toxins in the Body- Meeting the Challenge of Project Bioshield

Company Overview

Aethlon Medical, Inc. (OTCBB: AEMD) is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. Aethlon has published compelling human blood studies of the Hemopurifier™ to treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism. The Hemopurifier is a proprietary platform technology that converges the established scientific principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur.

James A. Joyce, President and Chief Executive Officer

As the founder of Aethlon Medical, Mr. Joyce has established the Company through a series of acquisitions and license agreements. In June of 2001, Mr. Joyce succeeded Franklyn S. Barry, Jr. as President and CEO of Aethlon Medical. Since that time, he has led the Company’s transition from treating harmful metals to treating HIV/AIDS, Hepatitis-C, and most recently, infectious biowarfare pathogens.

From February 1993 until founding Aethlon in May of 1998, Mr. Joyce was Chief Executive Officer of James Joyce & Associates, an organization that provided senior management consulting and investment banking advisory services to both private and publicly traded companies. Previously, Mr. Joyce was Chief Executive Officer of Mission Labs, Inc., and a principal in charge of U.S. operations for London Zurich Securities, Inc. Mr. Joyce is a graduate of the University of Maryland.

In 2005, Mr. Joyce testified before The House Committee on Homeland Security, Subcommittee on Emergency Preparedness, Science, and Technology in the hearing entitled "Project BioShield; Linking Bioterrorism Threats and Countermeasure Procurement to Enhance Terrorism Preparedness." He has also participated as a member of the Project BioShield panel at the Federal Biodefense Research Conference in Washington, D.C.

Safe Harbor Statement: Matters discussed in these presentations contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in these presentations the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company, and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.